Diagnostic I-131 scintigraphy in patients with differentiated thyroid cancer: No additional value of higher scan dose

Annals of Nuclear Medicine

Volumn 18, Issue 8, 2004, Pages 641-646

  Phan, Thi T H ^a   Van Tol, Karin M ^a   Links, Thera P ^a   Piers, D Albertus ^a   De Vries, Elisabeth G E ^a   Dullaart, Robin P F ^a   Jager, Pieter L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Diagnostic I 131 scanning; Differentiated thyroid carcinoma; Follow up protocol; Thyroglobulin

Indexed keywords

IODINE 131;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DOSE; RADIOISOTOPE THERAPY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROID SCINTISCANNING; THYROIDECTOMY;

EID: 13444306405     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02985956     Document Type: Article

References (17)

1. Schlumberger MJ. Papillary and follicular thyroid carcinoma. New Engl J Med 1998; 338: 297-306.
2. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86: 1447-1463.
3. Nemac J, Rohling S, Zamrazil V, Pohunkova D. Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers. J Nucl Med 1979; 20: 92-97.
4. Waxman A, Ramanna L, Chapman N, Chapman D, Brachman M, Tanasescu D, et al. The significance of I-131 scan dose in patients with thyroid cancer: Determination of ablation: Concise communication. J Nucl Med 1981; 22: 861-865.
5. Ramanna L, Waxman AD, Brachman MB, Tanasescu DE, Chapman N, Braunstein G. Treatment rationale in thyroid carcinoma: effect of scan dose. Clin Nucl Med 1985; 10: 687-689.
6. Sherman SI, Tielens ET, Sostre S, Wharam MD, Ladenson PW. Clinical utility of post-treatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994; 78: 629-634.
7. Greenler DP, Klein HA. The scope of false-positive iodine-131 images in thyroid carcinoma. Clin Nucl Med 1989; 14: 111-117.
8. Park HM, Perkins OW, Edmondson JW, Shnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994; 4: 49-54.
9. Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C, et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 1987; 28: 1888-1891.
10. 131I. J Nucl Med 2000; 41: 1198-1202.
11. Jeevanram RK, Shah DH, Sharma SM, Ganatra RD. Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Nucl Med Biol 1986; 13: 277-279.
12. Muratet JP, Dacer A, Minier JF, Larra F. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med 1998; 39: 1546-1550.
13. Legar FA, Izembart M, Dagousset F, Barritault L, Baillet G, Chevalier A, et al. Decreased uptake of thrapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. J Nucl Med 1998; 25: 242-246.
14. 131I-scanned and nonscanned individuals. J Clin Endocrinol Metab 2001; 86: 3507-3511.
15. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000; 85: 175-178.
16. Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, DeGroot LJ. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994; 79: 98-105.
17. 131I activities versus untreated patients. J Clin Endocrinol Metab 2001; 86: 4092-4097.